BioCentury
ARTICLE | Clinical News

GTx shares crater after incontinence readout

September 21, 2018 10:15 PM UTC

GTx Inc. (NASDAQ:GTXI) shed 92% of its value Friday, falling from the small cap band to trading at roughly the value of its cash, after the company's enobosarm (GTx-024) failed in the Phase II ASTRID study to treat stress urinary incontinence.

Among the 493 postmenopausal women enrolled in ASTRID, neither of two doses of enobosarm led to a significantly higher proportion of patients with a >50% reduction in incontinence episodes per day vs. placebo after 12 weeks (57.7% for 1 mg and 58.9% for 3 mg vs. 52.7% for placebo). Enobosarm is a non-steroidal selective androgen receptor modulator (SARM). ...

BCIQ Company Profiles

GTx Inc.